Citation

Pathak S, Kratochvil CJ, Rogers GM, Silva S, Vitiello B, Weller EB, March JS. Curr. Psychiatry Rep. 2005; 7(6): 429-434.

Affiliation

University of Cincinnati College of Medicine, Children's Hospital Medical Center, MLC # D-3014, 3333 Burnet Avenue, Cincinnati, OH 45229, USA. sanjeev.pathak@cchmc.org

Copyright

(Copyright © 2005, Holtzbrinck Springer Nature Publishing Group)

DOI

unavailable

PMID

16318820

Abstract

Adolescents with major depressive disorder (MDD), their families and clinicians experience significant challenges when weighing the potential risks versus benefits of available choices in the treatment of MDD. Although MDD is highly prevalent in adolescents and is associated with marked suffering, impairment and risk of suicide, the scientific data regarding the safety and efficacy of treatments for pediatric depression are limited. Controlled clinical trials have provided support for the use of psychotherapy and fluoxetine for the treatment of pediatric depression, but until recently no information on the comparative efficacy of these recommended interventions alone or in combination was available. The Treatment for Adolescents with Depression Study provides a very important therapeutic advance in the field by convincingly showing that combination treatment with cognitive behavioral therapy and fluoxetine has the best benefit to risk ratio for adolescents with moderate to severe depression, and is superior to monotherapy. Moreover, the study results confirm that fluoxetine alone is effective in the treatment of depressed adolescents.

Language: en